Aytu Biopharma (AYTU) Corporate presentation summary

Mission and therapeutic focus

• Dedicated to improving patient lives, with a focus on complex CNS conditions such as major depressive disorder (MDD) and ADHD.

• Portfolio includes novel therapeutics for MDD and ADHD, leveraging efficient M&A to expand branded prescription offerings.

Product portfolio and innovation

• EXXUA (gepirone ER) launched as a first-in-class MDD treatment with a novel 5HT1A agonist mechanism, avoiding common antidepressant side effects.

• ADHD brands include Adzenys XR-ODT and Cotempla XR-ODT, both extended-release orally disintegrating tablets with strong clinical data.

• Pediatric brands feature Karbinal ER and unique multivitamin supplements with novel ingredients.

Market opportunity and competitive positioning

• US MDD market exceeds $22B, with high unmet needs due to side effects and ineffectiveness of current therapies.

• EXXUA offers a differentiated profile: no sexual dysfunction or weight gain, once-daily dosing, and premium pricing.

• ADHD and pediatric portfolios maintain strong prescription volumes, supporting diversified revenue streams.